Skip to main content
. 2014 Jan 28;11(2):249–256. doi: 10.4314/ajtcam.v11i2.4

Table 4.

Effect of Diabegon® on VLDL & LDL level in MetS with Non-insulin dependent diabetes mellitus subjects of different age groups (N=58)

(Group) VLDL (mg/dl) LDL (mg/dl)
Initial (a) 6 month of therapy (b) 12 month
of theray(c)		 18 month
of therapy (d)		 Initial (a) 6 month of therapy (b) 12 month
of therapy(c)		 18 month
of therapy (d)
Group I
(35–50) ,N=10 		56.2±18.7 38.4±6.3 a* 22±1.76 a**b** 25.2±7.57 a**b** 113.7±30.2 87±55.9 71.9±15 a** 51.7±19 a**c*
Group II
(51–65) ,N=34 		33.8±5.8 24±11.3 a** 24.2±3.2 a** 25.1±9.4 a** 89.5±23 127.1±24.9 a** 106.2±42.3 a*b* 64±41.7 a*b**c**
Group III >65, N=14 26.7±6.6 31.4±2.8 a* 27.3±8.6 20.2±9.3 a*b**c* 109.2±20.1 100.5±56.8 96±7.1 a* 75±15.4 a**c**
CB-IV, N=43
FBS<145.9 		27±18.5 26.3±9.9 22.9±10.1 21.7±13b* 90.3±22.6 110.9±41.1 a* 108.7±51.3 a* 70±40 a*b*c**
CB-V, N=15
FBS>145.9 		39.04±8.24 26.3±3.3 a** 22±4.4 a**b* 28.7±5.3 a**c** 131.77±12.1 98.9±6.28 a** 96.07±11.2 a** 61±8.2 a**b**c**

FBS, fasting blood sugar; CB, Combination, data were analyzed by ANOVA Bonferroni t-test. Levels of significance were represented in the form of bcdefghP<0.001(**),bcdefghP<0.05(*) when compared with initial (a) group.